JFL Life Sciences Ltd
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]
- Market Cap ₹ 107 Cr.
- Current Price ₹ 32.4
- High / Low ₹ 37.2 / 12.0
- Stock P/E 18.8
- Book Value ₹ 11.8
- Dividend Yield 0.26 %
- ROCE 11.5 %
- ROE 9.76 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 61.6% CAGR over last 5 years
Cons
- The company has delivered a poor sales growth of 7.93% over past five years.
- Company has a low return on equity of 13.8% over last 3 years.
- Company has high debtors of 197 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
31.78 | 30.17 | 32.77 | 33.59 | 42.83 | 46.55 | 76.36 | |
30.45 | 28.31 | 30.61 | 28.23 | 38.91 | 42.00 | 68.74 | |
Operating Profit | 1.33 | 1.86 | 2.16 | 5.36 | 3.92 | 4.55 | 7.62 |
OPM % | 4.19% | 6.17% | 6.59% | 15.96% | 9.15% | 9.77% | 9.98% |
0.00 | 0.03 | 0.09 | 0.89 | 1.64 | 0.52 | 0.44 | |
Interest | 0.75 | 1.16 | 1.23 | 2.08 | 1.42 | 0.83 | 0.39 |
Depreciation | 0.15 | 0.24 | 0.28 | 0.37 | 0.43 | 0.44 | 0.71 |
Profit before tax | 0.43 | 0.49 | 0.74 | 3.80 | 3.71 | 3.80 | 6.96 |
Tax % | 27.91% | 28.57% | 27.03% | 26.05% | 24.53% | 13.16% | |
0.30 | 0.36 | 0.54 | 2.81 | 2.81 | 3.31 | 5.67 | |
EPS in Rs | 2.31 | 2.77 | 2.84 | 1.17 | 0.85 | 1.00 | 1.72 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8.31% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 12% |
TTM: | 72% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 62% |
3 Years: | 83% |
TTM: | 82% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 123% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 14% |
Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.42 | 0.42 | 0.50 | 8.02 | 11.00 | 11.00 | 11.00 |
Reserves | 4.59 | 4.95 | 6.38 | 3.27 | 21.27 | 24.58 | 27.91 |
8.41 | 9.33 | 16.82 | 15.85 | 7.18 | 5.69 | 10.49 | |
2.73 | 9.63 | 5.31 | 21.12 | 9.60 | 15.37 | 35.04 | |
Total Liabilities | 16.15 | 24.33 | 29.01 | 48.26 | 49.05 | 56.64 | 84.44 |
2.48 | 5.05 | 6.50 | 7.13 | 6.80 | 12.47 | 12.16 | |
CWIP | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
13.63 | 19.28 | 22.51 | 41.13 | 42.25 | 44.17 | 72.28 | |
Total Assets | 16.15 | 24.33 | 29.01 | 48.26 | 49.05 | 56.64 | 84.44 |
Cash Flows
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
-3.00 | 3.21 | -5.87 | 2.32 | -9.07 | 8.36 | |
-0.61 | -2.76 | -1.64 | -0.71 | 0.87 | -6.07 | |
3.61 | -0.19 | 7.25 | -1.46 | 8.07 | -2.31 | |
Net Cash Flow | 0.00 | 0.27 | -0.26 | 0.15 | -0.13 | -0.03 |
Ratios
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 110.95 | 153.16 | 131.54 | 215.15 | 191.58 | 197.20 |
Inventory Days | 21.43 | 51.75 | 72.47 | 211.64 | 130.01 | 148.72 |
Days Payable | 17.79 | 121.71 | 57.70 | 218.43 | 75.53 | 92.17 |
Cash Conversion Cycle | 114.58 | 83.20 | 146.31 | 208.36 | 246.06 | 253.76 |
Working Capital Days | 125.65 | 103.80 | 170.30 | 197.44 | 270.58 | 218.22 |
ROCE % | 11.74% | 10.26% | 23.13% | 15.41% | 11.47% |
Documents
Announcements
-
Outcome of Board Meeting
14 November 2024 - Jfl Life Sciences Limited has informed regarding Board meeting held on November 14, 2024.
-
Outcome of Board Meeting
14 November 2024 - Jfl Life Sciences Limited has informed regarding Outcome of Board Meeting held on November 14, 2024.
-
Financial Result Updates
14 November 2024 - Jfl Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
-
Board Meeting Intimation
5 November 2024 - JFL LIFE SCIENCES LIMITED has informed about Board Meeting to be held on 14-Nov-2024 to inter-alia consider and approve the Audited Financial results of the …
-
Updates
7 October 2024 - Jfl Life Sciences Limited has informed regarding 'Non-applicability of Corporate Governance Provisions'.
Business Overview:[1]
JFLLSL is a WHO-GMP Certified pharmaceutical company that manufactures and sells products across multiple markets. It specializes in Dry Powder Injectable Solid Oral Dosage Forms (Beta-Lactam & General)